Therapy with imatinib. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy14

K562 Cells Philadelphia Chromosome Cell Line, Tumor Neoplastic Stem Cells Bone Marrow Chromosomes, Human, Pair 9 Tumor Cells, Cultured Palate, Hard Hematopoietic Stem Cells Myeloid Progenitor Cells Interstitial Cells of Cajal Stromal Cells HL-60 Cells Cells, Cultured

Organisms3

Papio anubis Mice, Nude Mice, SCID

Diseases42

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Gastrointestinal Stromal Tumors Leukemia, Myeloid, Chronic-Phase Blast Crisis Gastrointestinal Neoplasms Philadelphia Chromosome Hypereosinophilic Syndrome Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Leukemia, Myeloid, Accelerated Phase Dermatofibrosarcoma Precursor Cell Lymphoblastic Leukemia-Lymphoma Neoplasm, Residual Muscle Cramp Disease Progression Fibromatosis, Aggressive Mastocytosis, Systemic Hypopigmentation Recurrence Pregnancy Complications, Neoplastic Lichenoid Eruptions Neoplasm Recurrence, Local Chordoma Leukemia Scleroderma, Diffuse Cecal Neoplasms Fibrosis Scleroderma, Systemic Gynecomastia Hypophosphatemia Splenomegaly Chromosome Aberrations Edema Mastocytosis Neutropenia Testicular Hydrocele Primary Myelofibrosis Nausea Jejunal Neoplasms Leukemia, Myelomonocytic, Chronic Exanthema Neoplasm Metastasis Thrombocytopenia

Chemicals and Drugs57

Benzamides Piperazines Pyrimidines Fusion Proteins, bcr-abl Antineoplastic Agents Protein Kinase Inhibitors Proto-Oncogene Proteins c-kit Receptor, Platelet-Derived Growth Factor alpha Proto-Oncogene Proteins c-abl Protein-Tyrosine Kinases Thiazoles Organic Cation Transporter 1 Receptors, Platelet-Derived Growth Factor Harringtonines Interferon-alpha Pyrroles Enzyme Inhibitors Biomarkers, Pharmacological Cytarabine Indoles Proto-Oncogene Proteins c-sis mRNA Cleavage and Polyadenylation Factors Hydroxyurea P-Glycoprotein src-Family Kinases Platelet-Derived Growth Factor RNA, Messenger Oncogene Proteins v-abl STAT5 Transcription Factor Stem Cell Factor Antigens, CD34 Orosomucoid Neoplasm Proteins Oncogene Proteins, Fusion Pyridines ATP-Binding Cassette Transporters Phenyl Ethers Phenylurea Compounds RNA, Neoplasm Benzenesulfonates Cytochrome P-450 CYP3A Niacinamide Aniline Compounds Phthalazines Quinolines Receptor, Macrophage Colony-Stimulating Factor Drugs, Investigational Proto-Oncogene Proteins c-akt raf Kinases Pyridones Tumor Markers, Biological Aclarubicin Farnesyltranstransferase Oxazepines Benzylisoquinolines Iridium Radioisotopes Class Ia Phosphatidylinositol 3-Kinase

Analytical, Diagnostic and Therapeutic Techniques and Equipment48

Cytogenetic Analysis Treatment Outcome Remission Induction Disease-Free Survival Drug Administration Schedule Antineoplastic Combined Chemotherapy Protocols Treatment Failure Drug Monitoring Salvage Therapy Survival Analysis Survival Rate Prognosis Inhibitory Concentration 50 Drug Approval Reverse Transcriptase Polymerase Chain Reaction Administration, Oral Follow-Up Studies Clinical Trials, Phase II as Topic In Situ Hybridization, Fluorescence Withholding Treatment DNA Mutational Analysis Clinical Trials as Topic Early Termination of Clinical Trials Kaplan-Meier Estimate Transplantation, Homologous Models, Economic Drug Screening Assays, Antitumor Hematopoietic Stem Cell Transplantation Neoadjuvant Therapy Blotting, Western Stem Cell Transplantation Clinical Trials, Phase III as Topic Therapies, Investigational Combined Modality Therapy Xenograft Model Antitumor Assays Immunohistochemistry Retrospective Studies Positron-Emission Tomography Chemotherapy, Adjuvant Maximum Tolerated Dose Clinical Trials, Phase I as Topic Molecular Targeted Therapy Chromatography, High Pressure Liquid Polymerase Chain Reaction Blood Cell Count Flow Cytometry Karyotyping Tomography, X-Ray Computed

Phenomena and Processes29

Drug Resistance, Neoplasm Genes, abl Philadelphia Chromosome Gene Expression Regulation, Leukemic Mutation Dose-Response Relationship, Drug Apoptosis Cell Proliferation Genes, sis Time Factors Phosphorylation Drug Synergism Inhibitory Concentration 50 Signal Transduction Drug Interactions Cell Survival Chromosomes, Human, Pair 9 Gene Expression Regulation, Neoplastic Exons Point Mutation Maximum Tolerated Dose Protein Structure, Tertiary Chromosome Aberrations Cell Division Genes, fms Drug Resistance Blood Cell Count Cell Cycle Drug Resistance, Multiple

Disciplines and Occupations2

Cytogenetics Immunohistochemistry

Anthropology, Education, Sociology and Social Phenomena2

Drug Approval United States Food and Drug Administration

Information Science1

Health Care16

Treatment Outcome Disease-Free Survival Treatment Failure Survival Analysis Survival Rate Follow-Up Studies Clinical Trials, Phase II as Topic Withholding Treatment Clinical Trials as Topic Early Termination of Clinical Trials Kaplan-Meier Estimate Models, Economic Clinical Trials, Phase III as Topic Retrospective Studies Clinical Trials, Phase I as Topic United States Food and Drug Administration

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Information Science Health Care

Benzamides Piperazines Pyrimidines Leukemia, Myelogenous, Chronic, BCR-ABL Positive Gastrointestinal Stromal Tumors Fusion Proteins, bcr-abl Antineoplastic Agents Protein Kinase Inhibitors Leukemia, Myeloid, Chronic-Phase Proto-Oncogene Proteins c-kit Drug Resistance, Neoplasm Receptor, Platelet-Derived Growth Factor alpha Genes, abl Proto-Oncogene Proteins c-abl K562 Cells Blast Crisis Protein-Tyrosine Kinases Thiazoles Cytogenetic Analysis Gastrointestinal Neoplasms Philadelphia Chromosome Hypereosinophilic Syndrome Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Treatment Outcome Remission Induction Organic Cation Transporter 1 Leukemia, Myeloid, Accelerated Phase Disease-Free Survival Receptors, Platelet-Derived Growth Factor Harringtonines Cell Line, Tumor Gene Expression Regulation, Leukemic Mutation Dose-Response Relationship, Drug Interferon-alpha Dermatofibrosarcoma Drug Administration Schedule Precursor Cell Lymphoblastic Leukemia-Lymphoma Apoptosis Antineoplastic Combined Chemotherapy Protocols Cell Proliferation Pyrroles Neoplasm, Residual Genes, sis Enzyme Inhibitors Treatment Failure Muscle Cramp Disease Progression Fibromatosis, Aggressive Mastocytosis, Systemic Time Factors Drug Monitoring Hypopigmentation Salvage Therapy Phosphorylation Survival Analysis Survival Rate Cytogenetics Biomarkers, Pharmacological Drug Synergism Prognosis Cytarabine Inhibitory Concentration 50 Drug Approval Indoles Proto-Oncogene Proteins c-sis mRNA Cleavage and Polyadenylation Factors Reverse Transcriptase Polymerase Chain Reaction Hydroxyurea Administration, Oral Signal Transduction P-Glycoprotein Follow-Up Studies Clinical Trials, Phase II as Topic Recurrence In Situ Hybridization, Fluorescence Withholding Treatment DNA Mutational Analysis Neoplastic Stem Cells src-Family Kinases Clinical Trials as Topic Platelet-Derived Growth Factor Early Termination of Clinical Trials Kaplan-Meier Estimate Pregnancy Complications, Neoplastic Drug Interactions Lichenoid Eruptions RNA, Messenger Papio anubis Cell Survival Oncogene Proteins v-abl Neoplasm Recurrence, Local Chordoma STAT5 Transcription Factor Transplantation, Homologous Models, Economic Leukemia Stem Cell Factor Drug Screening Assays, Antitumor Antigens, CD34

No FAQ available that match "therapy with imatinib"